Aurinia Pharmaceuticals (AUPH) Non-Current Assets (2016 - 2026)

Aurinia Pharmaceuticals has reported Non-Current Assets for 11 years, with the latest figure at $243.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 146.0% year-over-year to $243.8 million; the trailing twelve-month figure through Mar 2026 stood at $685.8 million (up 61.01% YoY), and the FY2025 full-year result was $259.6 million, up 149.52% from the prior year.
• Non-Current Assets for Q1 2026 stood at $243.8 million, down from $259.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $259.6 million in Q4 2025, with the low at $28.1 million in Q1 2023.
• Historically, Non-Current Assets has averaged $103.4 million across 5 years, with a median of $104.0 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 34.68% — and 2023, when it jumped 359.31%.
• Aurinia Pharmaceuticals' Non-Current Assets stood at $28.3 million in 2022, then jumped by 335.23% to $123.3 million in 2023, then declined by 15.59% to $104.0 million in 2024, then jumped by 149.52% to $259.6 million in 2025, then decreased by 6.11% to $243.8 million in 2026.
• The last three Non-Current Assets figures came in at $243.8 million (Q1 2026), $259.6 million (Q4 2025), and $88.8 million (Q3 2025), per Business Quant data.